Orion - Company Announcement

Orion upgrades full-year outlook for 2016

ORION CORPORATION      STOCK EXCHANGE RELEASE 15 JUNE 2016 at 10:20 a.m. EEST


Orion upgrades full-year outlook for 2016

Orion Corporation upgrades the full-year outlook estimate for 2016 provided on
2 February 2016. As to net sales, the year has started better than expected. At
the same time, costs have been well under control. Based on the good start for
the year the company estimates that the full-year net sales and operating profit
will be higher than estimated previously.

The new outlook estimate does not include potential capital gains, such as
potential capital gains of about EUR 11 million to the company from the
potential sales of Ekokem Corporation's shares owned by the company on the basis
of the tender offer for Ekokem Corporation's shares published by Fortum
Corporation.

New full-year outlook estimate for 2016, provided on 15 June 2016

Net sales are estimated to be slightly higher than in 2015 (net sales were EUR
1,016 million in 2015).

Operating profit without potential capital gains is estimated to exceed EUR 270
million (operating profit was EUR 267 million in 2015).


Previous full-year outlook estimate for 2016, provided on 2 February 2016

Net sales are estimated to be at similar level to 2015 (net sales were EUR
1,016 million in 2015).

Operating profit is estimated to exceed EUR 240 million.



Orion Corporation



 Timo Lappalainen    Olli Huotari
 President and CEO   SVP, Corporate Functions



Contact person:
Jari Karlson, CFO
tel. +358 50 966 2883


Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02101 Espoo, Finland
Homepage: www.orion.fi


Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. The core therapy areas of Orion's pharmaceutical R&D are
central nervous system (CNS) disorders, oncology and respiratory for which Orion
developes inhaled Easyhaler® pulmonary drugs.

Orion's net sales in 2015 amounted to EUR 1,016 million and the Company had
about 3,400 employees. Orion's A and B shares are listed on Nasdaq Helsinki.

[HUG#2020751]